Navigation Links
Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
Date:4/15/2008

/p>

About Piramed

Piramed is a biotech company whose mission is to discover and develop new medicines primarily for the treatment of cancer and immune inflammatory disorders such as arthritis and asthma. Piramed is a leading company in the discovery of highly selective drugs that inhibit different isoforms of PI3-K, enzymes that are increasingly recognized as key players in a wide variety of disease processes. The company's leadership in this area was recognized in 2005 when it secured a collaboration with Genentech in relation to its PI3-K alpha program. The company also has proprietary, unpartnered program targeting the PI3-K delta isoform that are in the later stages of pre-clinical development and certain earlier stage program involving a variety of molecular targets. Additional information is available on the Internet at http://www.piramed.com.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2007 Roche was named Top Company of the Year by Med Ad News, one of the Top 20 Employers (Science) and ranked the No. 1 Company to Sell For (Selling Power). In previous years, Roche has been named as a Top Company for Older Workers (AARP) and one of the Best Companies to Work For in America (Fortune). For additional information about the U.S. pharmaceuticals business, visit our websites: http://www.rocheusa.com or http://www.roche.us.

All trademarks used o
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
2. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
3. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
4. Roche responds to announcement of IDEAL hepatitis C trial results
5. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
6. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
9. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 AARP Foundation today announced it has ... suffering from the severe cold weather that has gripped much ... helping those in need; so to support these emergency relief ... to $250,000, which could mean up to $500,000 in aid. ...
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... ArvinMeritor (NYSE: ARM ) today announced that ... by Lin Cummins, senior vice president of Communications for ArvinMeritor, ... one of the most challenging economic times in history, I ... and individuals to help wipe out heart disease, the number ...
... positive cash flow from operationsBOSTON, Feb. 25 ... leader in radiology and medical image and information ... the fourth quarter and year ended December 31, ... Highlights Revenue : Total revenue for the ...
... New Veterans Health Council and Web Site Provide ... Vietnam Veterans of America (VVA) today formally debuted ... families, and health professionals a new resource for ... served in the military. The Veterans Health ...
... discomfort, scientists say , , WEDNESDAY, Feb. 25 (HealthDay News) -- ... the compound that gives chili peppers their fiery flavor, also ... study appearing Tuesday in the journal PLoS Biology , ... both pain and heat. , "The receptor acts like a ...
... University have precisely measured the impact of a high-fat ... dietary fat caused a 300 percent increase in metastasizing ... an imaging technique to document how increasing fat content ... Then they used another technique to count the number ...
... Medarex, Inc. (Nasdaq: MEDX ) announced today ... 31, 2008. Medarex,s net loss for the year ended December ... compared to a net loss of $27.1 million, or ($0.21) ... a gain of $151.8 million, or $1.18 per share, from ...
Cached Medicine News:Health News:ArvinMeritor Proud to Sponsor American Heart Association Campaign 2Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 2Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 3Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 4Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 5Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 6Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 7Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 8Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 9Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 10Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 11Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 12Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 13Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 14Health News:VVA Introduces Collaboration Between Veterans and Private Sector to Address Healthcare Needs for Vets 2Health News:New findings measure precise impact of fat on cancer spread 2Health News:New findings measure precise impact of fat on cancer spread 3Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 2Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 3Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 4Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 5Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 6Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 7Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 8Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 9Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 10Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 11Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 12
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Medicine Products: